BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

696 related articles for article (PubMed ID: 23887863)

  • 1. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
    Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
    Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
    Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct.
    Sasaki M; Matsubara T; Yoneda N; Nomoto K; Tsuneyama K; Sato Y; Nakanuma Y
    Histopathology; 2013 Feb; 62(3):446-57. PubMed ID: 23163606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
    Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
    Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
    Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
    Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma.
    Nakagawa S; Okabe H; Ouchi M; Tokunaga R; Umezaki N; Higashi T; Kaida T; Arima K; Kitano Y; Kuroki H; Mima K; Nitta H; Imai K; Hashimoto D; Yamashita YI; Chikamoto A; Baba H
    HPB (Oxford); 2018 Oct; 20(10):939-948. PubMed ID: 29759640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis.
    Sasaki M; Yamaguchi J; Itatsu K; Ikeda H; Nakanuma Y
    J Pathol; 2008 Jun; 215(2):175-83. PubMed ID: 18393368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
    Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
    Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
    Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
    Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
    Alimova I; Birks DK; Harris PS; Knipstein JA; Venkataraman S; Marquez VE; Foreman NK; Vibhakar R
    Neuro Oncol; 2013 Feb; 15(2):149-60. PubMed ID: 23190500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma.
    Zhang J; Chen L; Han L; Shi Z; Zhang J; Pu P; Kang C
    Cancer Lett; 2015 Jan; 356(2 Pt B):929-36. PubMed ID: 25444902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer.
    Ishikawa S; Hayashi H; Kinoshita K; Abe M; Kuroki H; Tokunaga R; Tomiyasu S; Tanaka H; Sugita H; Arita T; Yagi Y; Watanabe M; Hirota M; Baba H
    Int J Cancer; 2014 Dec; 135(11):2528-36. PubMed ID: 24346863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3.
    Tang B; Du J; Li Y; Tang F; Wang Z; He S
    Med Oncol; 2014 Nov; 31(11):271. PubMed ID: 25280519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery.
    Shi RY; Yang XR; Shen QJ; Yang LX; Xu Y; Qiu SJ; Sun YF; Zhang X; Wang Z; Zhu K; Qin WX; Tang ZY; Fan J; Zhou J
    Cancer; 2013 Mar; 119(5):993-1003. PubMed ID: 23132676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
    Zhou W; Wang J; Man WY; Zhang QW; Xu WG
    Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
    Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
    Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
    Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
    J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
    Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
    Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis.
    Ma J; Weng L; Wang Z; Jia Y; Liu B; Wu S; Cao Y; Sun X; Yin X; Shang M; Mao A
    Exp Cell Res; 2018 May; 366(2):103-113. PubMed ID: 29530475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
    Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA
    Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.